Obesity and coronary microvascular disease-implications for adipose tissue-mediated remote inflammatory response

Current Vascular Pharmacology

Volumn 12, Issue 3, 2014, Pages 453-461

  Bagi, Zsolt ^a   Broskova, Zuzana ^a   Feher, Attila ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Adiponectin; Adipose tissue; Coronary artery; IL 6; Leptin; Obesity; Resistin; TNF

Indexed keywords

ACETYLCHOLINE; ADIPOCYTOKINE; ADIPONECTIN; CHLOROTRIANISENE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 6; LEPTIN; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; RESISTIN; STRESS ACTIVATED PROTEIN KINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; VASCULOTROPIN;

ACUTE HEART INFARCTION; ADIPOSE TISSUE; ARTICLE; BODY MASS; CAPILLARY DENSITY; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; CORONARY MICROVASCULAR DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; FOREARM BLOOD FLOW; HEART FAILURE; HEART MUSCLE BLOOD FLOW; HEART MUSCLE PERFUSION; HUMAN; HYPERTENSION; MICROCIRCULATION; MICROVASCULATURE; OBESITY; OXIDATIVE STRESS; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; VASCULAR RESISTANCE; VASCULITIS; VASODILATATION;

EID: 84922391966     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/1570161112666140423221843     Document Type: Article

References (128)

1. Hall JE, Brands MW, Henegar JR. Mechanisms of hypertension and kidney disease in obesity. Ann N Y Acad Sci 1999; 892: 91-107.
2. Martin JW, Briesmiester K, Bargardi A, Muzik O, Mosca L, Duvernoy CS. Weight changes and obesity predict impaired resting and endothelium-dependent myocardial blood flow in postmenopausal women. Clin Cardiol 2005; 28(1): 13-8.
3. Schindler TH, Cardenas J, Prior JO, et al. Relationship between increasing body weight, insulin resistance, inflammation, adipocytokine leptin, and coronary circulatory function. J Am Coll Cardiol 2006; 47(6): 1188-95.
4. Quercioli A, Pataky Z, Montecucco F, et al. Coronary Vasomotor Control in Obesity and Morbid Obesity Contrasting Flow Responses With Endocannabinoids, Leptin, and Inflammation. Jacc-Cardiovasc Imag 2012; 5(8): 805-15.
5. Vincenti GM, Ambrosio G, Hyacinthe JN, et al. Matching between regional coronary vasodilator capacity and corresponding circumferential strain in individuals with normal and increasing body weight. J Nucl Cardiol 2012; 19(4): 693-703.
6. Wang L, Jerosch-Herold M, Jacobs DR, Jr, Shahar E, Folsom AR. Coronary risk factors and myocardial perfusion in asymptomatic adults: the Multi-Ethnic Study of Atherosclerosis (MESA). J Am Coll Cardiol 2006; 47(3): 565-72.
7. Bashan N, Kovsan J, Kachko I, Ovadia H, Rudich A. Positive and negative regulation of insulin signaling by reactive oxygen and nitrogen species. Physiol Rev 2009; 89(1): 27-71.
8. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005; 26(3): 439-51.
9. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005; 96(9): 939-49.
10. Knudson JD, Dincer UD, Zhang C, et al. Leptin receptors are expressed in coronary arteries, and hyperleptinemia causes significant coronary endothelial dysfunction. Am J Physiol Heart Circ Physiol 2005; 289(1): H48-56.
11. Kougias P, Chai H, Lin PH, Lumsden AB, Yao Q, Chen C. Adipocyte-derived cytokine resistin causes endothelial dysfunction of porcine coronary arteries. J Vasc Surg 2005; 41(4): 691-8.
12. Dick GM, Katz PS, Farias M 3rd, et al. Resistin impairs endothelium-dependent dilation to bradykinin, but not acetylcholine, in the coronary circulation. Am J Physiol Heart Circ Physiol 2006; 291(6): H2997-3002.
13. Picchi A, Gao X, Belmadani S, et al. Tumor necrosis factor-alpha induces endothelial dysfunction in the prediabetic metabolic syndrome. Circ Res 2006; 99(1): 69-77.
14. Rutkowski JM, Davis KE, Scherer PE. Mechanisms of obesity and related pathologies: the macro-and microcirculation of adipose tissue. FEBS J 2009; 276(20): 5738-46.
15. Greenstein AS, Khavandi K, Withers SB, et al. Local inflammation and hypoxia abolish the protective anticontractile properties of perivascular fat in obese patients. Circulation 2009; 119(12): 1661-70.
16. Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997; 385(6618): 729-33.
17. Fiorentino L, Vivanti A, Cavalera M, et al. Increased tumor necrosis factor alpha-converting enzyme activity induces insulin resistance and hepatosteatosis in mice. Hepatology 2010; 51(1): 103-10.
18. Monroy A, Kamath S, Chavez AO, et al. Impaired regulation of the TNF-alpha converting enzyme/tissue inhibitor of metalloproteinase 3 proteolytic system in skeletal muscle of obese type 2 diabetic patients: a new mechanism of insulin resistance in humans. Diabetologia 2009; 52(10): 2169-81.
19. Lavie CJ, Messerli FH. Cardiovascular adaptation to obesity and hypertension. Chest 1986; 90(2): 275-9.
20. Iacobellis G. True uncomplicated obesity is not related to increased left ventricular mass and systolic dysfunction. J Am Coll Cardiol 2004; 44(11): 2257.
21. Peterson LR, Soto PF, Herrero P, et al. Impact of gender on the myocardial metabolic response to obesity. JACC Cardiovasc Imaging 2008; 1(4): 424-33.
22. Motivala AA, Rose PA, Kim HM, et al. Cardiovascular risk, obesity, and myocardial blood flow in postmenopausal women. J Nucl Cardiol 2008; 15(4): 510-7.
23. Chilian WM. Coronary microcirculation in health and disease. Summary of an NHLBI workshop. Circulation 1997; 95(2): 522-8.
24. Jones CJ, Kuo L, Davis MJ, Chilian WM. Regulation of coronary blood flow: coordination of heterogeneous control mechanisms in vascular microdomains. Cardiovasc Res 1995; 29(5): 585-96.
25. Fulop T, Jebelovszki E, Erdei N, et al. Adaptation of vasomotor function of human coronary arterioles to the simultaneous presence of obesity and hypertension. Arterioscler Thromb Vasc Biol 2007; 27(11): 2348-54.
26. Oltman CL, Richou LL, Davidson EP, Coppey LJ, Lund DD, Yorek MA. Progression of coronary and mesenteric vascular dysfunction in Zucker obese and Zucker diabetic fatty rats. Am J Physiol Heart Circ Physiol 2006; 291(4): H1780-7.
27. Katakam PV, Tulbert CD, Snipes JA, Erdos B, Miller AW, Busija DW. Impaired insulin-induced vasodilation in small coronary arteries of Zucker obese rats is mediated by reactive oxygen species. Am J Physiol Heart Circ Physiol 2005; 288(2): H854-60.
28. Henderson KK, Turk JR, Rush JW, Laughlin MH. Endothelial function in coronary arterioles from pigs with early-stage coronary disease induced by high-fat, high-cholesterol diet: effect of exercise. J Appl Physiol 2004; 97(3): 1159-68.
29. Jebelovszki E, Kiraly C, Erdei N, et al. High-fat diet-induced obesity leads to increased NO sensitivity of rat coronary arterioles: role of soluble guanylate cyclase activation. Am J Physiol Heart Circ Physiol 2008; 294(6): H2558-64.
30. Prakash R, Mintz JD, Stepp DW. Impact of obesity on coronary microvascular function in the Zucker rat. Microcirculation 2006; 13(5): 389-96.
31. Setty S, Sun W, Tune JD. Coronary blood flow regulation in the prediabetic metabolic syndrome. Basic Res Cardiol 2003; 98(6): 416-23.
32. Borbouse L, Dick GM, Payne GA, et al. Contribution of BK(Ca) channels to local metabolic coronary vasodilation: Effects of metabolic syndrome. Am J Physiol Heart Circ Physiol 2010; 298(3): H966-73.
33. Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. N Engl J Med 1995; 332(10): 621-8.
34. Kadowaki T, Hara K, Yamauchi T, Terauchi Y, Tobe K, Nagai R. Molecular mechanism of insulin resistance and obesity. Exp Biol Med (Maywood) 2003; 228(10): 1111-7.
35. Ahima RS, Qi Y, Singhal NS, Jackson MB, Scherer PE. Brain adipocytokine action and metabolic regulation. Diabetes 2006; 55 Suppl 2: S145-54.
36. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006; 116(7): 1784-92.
37. Patel SD, Rajala MW, Rossetti L, Scherer PE, Shapiro L. Disulfide-dependent multimeric assembly of resistin family hormones. Science 2004; 304(5674): 1154-8.
38. Miyazawa-Hoshimoto S, Takahashi K, Bujo H, Hashimoto N, Yagui K, Saito Y. Roles of degree of fat deposition and its localization on VEGF expression in adipocytes. Am J Physiol Endocrinol Metab 2005; 288(6): E1128-36.
39. Maury E, Noel L, Detry R, Brichard SM. In vitro hyperresponsiveness to tumor necrosis factor-alpha contributes to adipokine dysregulation in omental adipocytes of obese subjects. J Clin Endocrinol Metab 2009; 94(4): 1393-400.
40. Bastard JP, Lagathu C, Caron M, Capeau J. Point-counterpoint: Interleukin-6 does/does not have a beneficial role in insulin sensitivity and glucose homeostasis. J Appl Physiol 2007; 102(2): 821-2.
41. Kanda H, Tateya S, Tamori Y, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006; 116(6): 1494-505.
42. Pickup JC, Chusney GD, Thomas SM, Burt D. Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes. Life Sci 2000; 67(3): 291-300.
43. Trayhurn P, Wang B, Wood IS. Hypoxia in adipose tissue: a basis for the dysregulation of tissue function in obesity? Br J Nutr 2008; 100(2): 227-35.
44. Halberg N, Khan T, Trujillo ME, et al. Hypoxia-inducible factor 1alpha induces fibrosis and insulin resistance in white adipose tissue. Mol Cell Biol 2009; 29(16): 4467-83.
45. Jiang CT, Qu AJ, Matsubara T, et al. Disruption of Hypoxia-Inducible Factor 1 in Adipocytes Improves Insulin Sensitivity and Decreases Adiposity in High-Fat Diet-Fed Mice. Diabetes 2011; 60(10): 2484-95.
46. Lehr S, Hartwig S, Lamers D, et al. Identification and Validation of Novel Adipokines Released from Primary Human Adipocytes. Mol Cell Proteomics 2012; 11(1): M111.010504.
47. Osborn O, Olefsky JM. The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med 2012; 18(3): 363-74.
48. Ouwens DM, Sell H, Greulich S, Eckel J. The role of epicardial and perivascular adipose tissue in the pathophysiology of cardiovascular disease. J Cell Mol Med 2010; 14(9): 2223-34.
49. Liu ML, Liu F. Transcriptional and post-translational regulation of adiponectin. Biochem J 2010; 425: 41-52.
50. Shibata R, Sato K, Pimentel DR, et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK-and COX-2 dependent mechanisms. Nat Med 2005; 11(10): 1096-103.
51. Jung CH, Kim MS. Molecular mechanisms of central leptin resistance in obesity. Arch Pharm Res 2013; 36(2): 201-7.
52. Allard C, Doyon M, Brown C, Carpentier AC, Langlois MF, Hivert MF. Lower leptin levels are associated with higher risk of weight gain over 2 years in healthy young adults. Appl Physiol Nutr Metab 2013; 38(3): 280-5.
53. Fried SK, Ricci MR, Russell CD, Laferrere B. Regulation of leptin production in humans. J Nutr 2000; 130(12): 3127S-31S.
54. Lee MJ, Wang YX, Ricci MR, Sullivan S, Russell CD, Fried SK. Acute and chronic regulation of leptin synthesis, storage, and secretion by insulin and dexamethasone in human adipose tissue. Am J Physiol-Endoc M 2007; 292(3): E858-E64.
55. Payne GA, Borbouse L, Kumar S, et al. Epicardial perivascular adipose-derived leptin exacerbates coronary endothelial dysfunction in metabolic syndrome via a protein kinase C-beta pathway. Arterioscler Thromb Vasc Biol 2010; 30(9): 1711-7.
56. Korda M, Kubant R, Patton S, Malinski T. Leptin-induced endothelial dysfunction in obesity. Am J Physiol-Heart C 2008; 295(4): H1514-H21.
57. Chen C, Jiang J, Lu JM, et al. Resistin decreases expression of endothelial nitric oxide synthase through oxidative stress in human coronary artery endothelial cells. Am J Physiol Heart Circ Physiol 2010; 299(1): H193-201.
58. Singhal A, Farooqi IS, Cole TJ, et al. Influence of leptin on arterial distensibility: a novel link between obesity and cardiovascular disease? Circulation 2002; 106(15): 1919-24.
59. Brook RD, Bard RL, Bodary PF, et al. Blood pressure and vascular effects of leptin in humans. Metab Syndr Relat Disord 2007; 5(3): 270-4.
60. Oflaz H, Ozbey N, Mantar F, et al. Determination of endothelial function and early atherosclerotic changes in healthy obese women. Diabetes Nutr Metab 2003; 16(3): 176-81.
61. Ye F, Than A, Zhao YY, Goh KH, Chen P. Vesicular storage, vesicle trafficking, and secretion of leptin and resistin: the similarities, differences, and interplays. J Endocrinol 2010; 206(1): 27-36.
62. Banerjee RR, Lazar MA. Resistin: molecular history and prognosis. J Mol Med-Jmm 2003; 81(4): 218-26.
63. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation. 2005; 111(7):932-9.
64. Ohmori R, Momiyama Y, Kato R, et al. Associations between serum resistin levels and insulin resistance, inflammation, and coronary artery disease. J Am Coll Cardiol 2005; 46(2): 379-80.
65. Momiyama Y, Ohmori R, Uto-Kondo H, et al. Serum Resistin Levels and Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention. J Atheroscler Thromb 2011; 18(2): 108-14.
66. Verma S, Li SH, Wang CH, et al. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 2003; 108(6): 736-40.
67. Chemaly ER, Hadri L, Zhang S, et al. Long-term in vivo resistin overexpression induces myocardial dysfunction and remodeling in rats. J Mol Cell Cardiol 2011; 51(2):144-55.
68. Wassmann S, Stumpf M, Strehlow K, et al. Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circ Res 2004; 94(4): 534-41.
69. Kusminski CM, da Silva NF, Creely SJ, et al. The in vitro effects of resistin on the innate immune signaling pathway in isolated human subcutaneous adipocytes. J Clin Endocr Metab 2007; 92(1): 270-6.
70. Yang JYO, Park Y, Zhang HR, et al. Feed-forward signaling of TNF-alpha and NF-kappa B via IKK-beta pathway contributes to insulin resistance and coronary arteriolar dysfunction in type 2 diabetic mice. Am J Physiol-Heart C 2009; 296(6): H1850-H8.
71. Zhang CH, Hein TW, Wang W, Ren Y, Shipley RD, Kuo L. Activation of JNK and xanthine oxidase by TNF-alpha impairs nitric oxide-mediated dilation of coronary arterioles. J Mol Cell Cardiol 2006; 40(2): 247-57.
72. Virdis A, Santini F, Colucci R, et al. Vascular Generation of Tumor Necrosis Factor-alpha Reduces Nitric Oxide Availability in Small Arteries From Visceral Fat of Obese Patients. J Am Coll Cardiol 2011; 58(3): 238-47.
73. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose Expression of Tumor-Necrosis-Factor-Alpha -Direct Role in Obesity-Linked Insulin Resistance. Science 1993; 259(5091): 87-91.
74. Dandona P, Weinstock R, Thusu K, Abdel-Rahman E, Aljada A, Wadden T. Tumor necrosis factor-alpha in sera of obese patients: Fall with weight loss. J Clin Endocr Metab 1998; 83(8): 2907-10.
75. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased Adipose-Tissue Expression of Tumor-Necrosis-Factor-Alpha in Human Obesity and Insulin-Resistance. J Clin Invest 1995; 95(5): 2409-15.
76. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. The Expression of Tumor-Necrosis-Factor in Human Adipose-Tissue -Regulation by Obesity, Weight-Loss, and Relationship to Lipoprotein-Lipase. J Clin Invest 1995; 95(5): 2111-9.
77. Klemm P, Warner TD, Hohlfeld T, Corder R, Vane JR. Endothelin-1 Mediates Ex-Vivo Coronary Vasoconstriction Caused by Exogenous and Endogenous Cytokines. Proc Natl Acad Sci USA 1995; 92(7): 2691-5.
78. Wagner EM. TNF-alpha induced bronchial vasoconstriction. Am J Physiol-Heart C 2000; 279(3): H946-H51.
79. Baudry N, Vicaut E. Role of Nitric-Oxide in Effects of Tumor-Necrosis-Factor-Alpha on Microcirculation in Rat. J Appl Physiol 1993; 75(6): 2392-9.
80. Brian JE, Faraci FM. Tumor necrosis factor-alpha-induced dilatation of cerebral arterioles. Stroke 1998; 29(2): 509-15.
81. Patel JN, Jager A, Schalkwijk C, et al. Effects of tumour necrosis factor-alpha in the human forearm: blood flow and endothelin-I release. Clin Sci 2002; 103(4): 409-15.
82. Cheranov SY, Jaggar JH. TNF-alpha dilates cerebral arteries via NAD(P)H oxidase-dependent Ca2+ spark activation. Am J Physiol-Cell Ph 2006; 290(4): C964-C71.
83. Tesauro M, Schinzari F, Rovella V, et al. Tumor necrosis factor-alpha antagonism improves vasodilation during hyperinsulinemia in metabolic syndrome. Diabetes Care 2008; 31(7): 1439-41.
84. Sewter CP, Digby JE, Blows F, Prins J, O'Rahilly S. Regulation of tumour necrosis factor-alpha release from human adipose tissue in vitro. J Endocrinol 1999; 163(1): 33-8.
85. Xu HY, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112(12): 1821-30.
86. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112(12): 1796-808.
87. Baker AR, da Silva NF, Quinn DW, et al. Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease. Cardiovasc Diabetol 2006; 5: 1.
88. Kriegler M, Perez C, Defay K, Albert I, Lu SD. A Novel Form of Tnf/Cachectin Is a Cell-Surface Cyto-Toxic Transmembrane Protein-Ramifications for the Complex Physiology of Tnf. Cell 1988; 53(1): 45-53.
89. Moss ML, Jin SLC, Milla ME, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 1997; 385(6618): 733-6.
90. Federici M, Hribal ML, Menghini R, Kanno H, Marchetti V, Porzio O, et al. Timp3 deficiency in insulin receptor-haploinsufficient mice promotes diabetes and vascular inflammation via increased TNF-alpha. J Clin Invest. 2005; 115(12): 3494-505.
91. Kawasaki S, Motoshima H, Hanatani S, et al. Regulation of TNF alpha converting enzyme activity in visceral adipose tissue of obese mice. Biochem Bioph Res Co 2013; 430(4): 1189-94.
92. de Meijer VE, Le HD, Meisel JA, Sharma AK, Popov Y, Puder M. Tumor Necrosis Factor alpha-Converting Enzyme Inhibition Reverses Hepatic Steatosis and Improves Insulin Sensitivity Markers and Surgical Outcome in Mice. Plos One 2011; 6(9): e25587.
93. Gupte M, Boustany-Kari CM, Bharadwaj K, et al. ACE2 is expressed in mouse adipocytes and regulated by a high-fat diet. Am J Physiol-Reg I 2008; 295(3): R781-R8.
94. McConway MG, Johnson D, Kelly A, Griffin D, Smith J, Wallace AM. Differences in circulating concentrations of total, free and bound leptin relate to gender and body composition in adult humans. Ann Clin Biochem 2000; 37(Pt 5): 717-23.
95. Wallace AM, McMahon AD, Packard CJ, et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 2001; 104(25): 3052-6.
96. Wolk R, Berger P, Lennon RJ, Brilakis ES, Johnson BD, Somers VK. Plasma leptin and prognosis in patients with established coronary atherosclerosis. J Am Coll Cardiol 2004; 44(9): 1819-24.
97. Soderberg S, Ahren B, Jansson JH, et al. Leptin is associated with increased risk of myocardial infarction. J Intern Med 1999; 246(4): 409-18.
98. Nakagawa K, Higashi Y, Sasaki S, Oshima T, Matsuura H, Chayama K. Leptin causes vasodilation in humans. Hypertens Res 2002; 25(2): 161-5.
99. Cleland SJ, Sattar N, Petrie JR, Forouhi NG, Elliott HL, Connell JM. Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin Sci (Lond) 2000; 98(5): 531-5.
100. Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999; 100(25): 2473-6.
101. Kumada M, Kihara S, Sumitsuji S, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23(1): 85-9.
102. Rothenbacher D, Brenner H, Marz W, Koenig W. Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers. Eur Heart J 2005; 26(16): 1640-6.
103. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291(14): 1730-7.
104. Zhang H, Park Y, Zhang C. Coronary and aortic endothelial function affected by feedback between adiponectin and tumor necrosis factor alpha in type 2 diabetic mice. Arterioscler Thromb Vasc Biol 2010; 30(11):2156-63.
105. Shimabukuro M, Higa N, Asahi T, et al. Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J Clin Endocrinol Metab 2003; 88(7): 3236-40.
106. Azuma K, Katsukawa F, Oguchi S, et al. Correlation between serum resistin level and adiposity in obese individuals. Obes Res 2003; 11(8): 997-1001.
107. Lupattelli G, Marchesi S, Ronti T, et al. Endothelial dysfunction in vivo is related to monocyte resistin mRNA expression. J Clin Pharm Ther 2007; 32(4): 373-9.
108. Yang B, Li M, Chen B, Li TD. Resistin involved in endothelial dysfunction among preclinical Tibetan male young adults. J Renin Angiotensin Aldosterone Syst 2010; 13(4): 420-5.
109. Pfeiffer A, Janott J, Mohlig M, et al. Circulating tumor necrosis factor alpha is elevated in male but not in female patients with type II diabetes mellitus. Horm Metab Res 1997; 29(3): 111-4.
110. Katsuki A, Sumida Y, Murashima S, et al. Serum levels of tumor necrosis factor-alpha are increased in obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1998; 83(3): 859-62.
111. Nilsson J, Jovinge S, Niemann A, Reneland R, Lithell H. Relation between plasma tumor necrosis factor-alpha and insulin sensitivity in elderly men with non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1998; 18(8): 1199-202.
112. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000; 101(18): 2149-53.
113. Zhang HF, Xie SL, Wang JF, Chen YX, Wang Y, Huang TC. Tumor necrosis factor-alpha G-308A gene polymorphism and coronary heart disease susceptibility: an updated meta-analysis. Thromb Res 2011; 127(5): 400-5.
114. Zhang C, Hein TW, Wang W, Ren Y, Shipley RD, Kuo L. Activation of JNK and xanthine oxidase by TNF-alpha impairs nitric oxide-mediated dilation of coronary arterioles. J Mol Cell Cardiol 2006; 40(2): 247-57.
115. Gao X, Xu X, Belmadani S, et al. TNF-alpha contributes to endothelial dysfunction by upregulating arginase in ischemia/reperfusion injury. Arterioscler Thromb Vasc Biol 2007; 27(6): 1269-75.
116. Zhang C, Xu X, Potter BJ, et al. TNF-alpha contributes to endothelial dysfunction in ischemia/reperfusion injury. Arterioscler Thromb Vasc Biol 2006; 26(3): 475-80.
117. Gao X, Zhang H, Belmadani S, et al. Role of TNF-alpha-induced reactive oxygen species in endothelial dysfunction during reperfusion injury. Am J Physiol Heart Circ Physiol 2008; 295(6): H2242-9.
118. Katz SD, Rao R, Berman JW, et al. Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure. Relation to nitric oxide-dependent vasodilation in the forearm circulation. Circulation 1994; 90(1): 12-6.
119. Hurlimann D, Forster A, Noll G, et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002; 106(17): 2184-7.
120. Chia S, Qadan M, Newton R, Ludlam CA, Fox KA, Newby DE. Intra-arterial tumor necrosis factor-alpha impairs endothelium-dependent vasodilatation and stimulates local tissue plasminogen activator release in humans. Arterioscler Thromb Vasc Biol 2003; 23(4): 695-701.
121. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19(4): 972-8.
122. Esposito K, Pontillo A, Di Palo C, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003; 289(14): 1799-804.
123. Cesari M, Penninx BW, Newman AB, et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003; 108(19): 2317-22.
124. Pai JK, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004; 351(25): 2599-610.
125. Pradhan AD, Manson JE, Rossouw JE, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA 2002; 288(8): 980-7.
126. Park Y, Capobianco S, Gao X, Falck JR, Dellsperger KC, Zhang C. Role of EDHF in type 2 diabetes-induced endothelial dysfunction. Am J Physiol Heart Circ Physiol 2008; 295(5): H1982-8.
127. Vita JA, Keaney JF Jr, Larson MG, et al. Brachial artery vasodilator function and systemic inflammation in the Framingham Offspring Study. Circulation 2004; 110(23): 3604-9.
128. Lee KW, Blann AD, Lip GY. Inter-relationships of indices of endothelial damage/dysfunction [circulating endothelial cells, von Willebrand factor and flow-mediated dilatation] to tissue factor and interleukin-6 in acute coronary syndromes. Int J Cardiol 2006; 111(2): 302-8.